C Triplitt
Overview
Explore the profile of C Triplitt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abdelgani S, Puckett C, Adams J, Triplitt C, DeFronzo R, Abdul-Ghani M
J Clin Endocrinol Metab
. 2021 Aug;
106(12):3497-3504.
PMID: 34343296
Context: The results of the present study demonstrate that beta cell function in newly diagnosed T2DM patients is the key predictor of response to glucose lowering medications and provides a...
2.
Triplitt C, Solis-Herrera C, Cersosimo E, Abdul-Ghani M, DeFronzo R
Expert Opin Pharmacother
. 2015 Nov;
16(18):2819-33.
PMID: 26583910
Introduction: Many patients with type 2 diabetes mellitus (T2DM) fail to achieve the desired A1c goal because the antidiabetic medications used do not correct the underlying pathophysiologic abnormalities and monotherapy...
3.
Abdul-Ghani M, Puckett C, Triplitt C, Maggs D, Adams J, Cersosimo E, et al.
Diabetes Obes Metab
. 2014 Nov;
17(3):268-75.
PMID: 25425451
Aim: To test our hypothesis that initiating therapy with a combination of agents known to improve insulin secretion and insulin sensitivity in subjects with new-onset diabetes would produce greater, more...
4.
Fernandez M, Gastaldelli A, Triplitt C, Hardies J, Casolaro A, PETZ R, et al.
Diabetes Obes Metab
. 2011 May;
13(10):893-902.
PMID: 21615671
Aim: To assess the effect of muraglitazar, a dual peroxisome proliferator-activated receptor (PPAR)γ-α agonist, versus placebo on metabolic parameters and body composition in subjects with type 2 diabetes mellitus (T2DM)....
5.
Cersosimo E, Gastaldelli A, Cervera A, Wajcberg E, Sriwijilkamol A, Fernandez M, et al.
J Clin Endocrinol Metab
. 2011 Mar;
96(6):1763-70.
PMID: 21411546
Objective: Our objective was to examine the mechanisms via which exenatide attenuates postprandial hyperglycemia in type 2 diabetes mellitus (T2DM). Study Design: Seventeen T2DM patients (44 yr; seven females, 10...
6.
Joya-Galeana J, Fernandez M, Cervera A, Reyna S, Ghosh S, Triplitt C, et al.
Diabetes Metab Res Rev
. 2011 Feb;
27(4):373-82.
PMID: 21309063
Background: To test potential differences between the actions of anti-diabetic medications, we examined the effects of oral hypoglycaemic agents versus glargine-apidra insulin therapy in T2DM. Methods: T2DM subjects were randomized...
7.
Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo R
Kidney Int
. 2007 Sep;
72(11):1367-73.
PMID: 17805239
Thiazolidinediones are insulin-sensitizing compounds that reduce plasma glucose and improve the lipid profile of type 2 diabetic patients. We determined the effect of rosiglitazone in 15 type 2 diabetic patients...
8.
Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, et al.
Diabetologia
. 2002 Jan;
44(12):2210-9.
PMID: 11793023
Aims/hypothesis: We aimed to examine the mechanisms by which rosiglitazone improves glycaemic control in Type II (non-insulin-dependent) diabetic patients. Methods: Altogether 29 diet-treated diabetic patients were assigned at random to...